+検索条件
-Structure paper
タイトル | Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19. |
---|---|
ジャーナル・号・ページ | J Virol, Vol. 97, Issue 11, Page e0144823, Year 2023 |
掲載日 | 2023年11月30日 |
著者 | Gang Ye / Ruangang Pan / Fan Bu / Jian Zheng / Alise Mendoza / Wei Wen / Lanying Du / Benjamin Spiller / Brian E Wadzinski / Bin Liu / Stanley Perlman / Fang Li / |
PubMed 要旨 | The COVID-19 pandemic exposed limitations of conventional antibodies as therapeutics, including high cost, limited potency, ineffectiveness against new viral variants, and primary reliance on ...The COVID-19 pandemic exposed limitations of conventional antibodies as therapeutics, including high cost, limited potency, ineffectiveness against new viral variants, and primary reliance on injection-only delivery. Nanobodies are single-domain antibodies with therapeutic potentials. We discovered three anti-SARS-CoV-2 nanobodies, named Nanosota-2, -3, and -4, from an immunized alpaca. Nanosota-2 is super potent against prototypic SARS-CoV-2, Nanosota-3 is highly potent against the omicron variant, and Nanosota-4 is effective against both SARS-CoV-1 and SARS-CoV-2. In addition to their super potency and combined broad antiviral spectrum, these nanobodies are cost-effective, can be easily adapted to new viral variants through phage display, and can potentially be administered as inhalers. The Nanosota series are powerful therapeutic candidates to combat circulating SARS-CoV-2 and prepare for possible future coronavirus pandemics. |
リンク | J Virol / PubMed:37855638 / PubMed Central |
手法 | EM (単粒子) |
解像度 | 2.5 - 5.6 Å |
構造データ | EMDB-29794, PDB-8g72: EMDB-29795, PDB-8g73: EMDB-29796, PDB-8g74: EMDB-29797, PDB-8g75: |
化合物 | ChemComp-NAG: |
由来 |
|
キーワード | VIRAL PROTEIN/IMMUNE SYSTEM (ウイルス性) / SARS-CoV-2 (SARSコロナウイルス2) / VIRAL PROTEIN-IMMUNE SYSTEM complex (ウイルス性) / Nanobody (ナノボディ) |